REFERENCES
- Abdel-Wahab, N., M. Shah, M. A. Lopez-Olivo, et al. 2018. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Annals of Internal Medicine 168 (2):121–30. doi:10.7326/M17-2073.
- Calabrese, L., and X. Mariette. 2018. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. Annals of the Rheumatic Diseases 77 (2):162–64. doi:10.1136/annrheumdis-2017-212061.
- Cappelli, L. C., K. Gutierrez, C. O. Bingham 3rd, et al. 2017. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care & Research (Hoboken) 69 (11):1751–63. doi:10.1002/acr.23177.
- Jecker, N. S., A. G. Wightman, A. R. Rosenberg, and D. S. Diekema. 2018. Ethical guidance for selecting clinical trials to receive limited space in an immunotherapy production facility. American Journal of Bioethics 18 (4):58–67.
- Kostine, M., L. Rouxel, T. Barnetche, et al. 2017. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—Clinical aspects and relationship with tumour response: A single-centre prospective cohort study. Annals of the Rheumatic Diseases 77 (3):393–98. doi:10.1136/annrheumdis-2017-212257.
- Oshima, Y., T. Tanimoto, K. Yuji, et al. 2018. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncology January 11. Epub ahead of print. doi:10.1001/jamaoncol.2017.4526.